Marc Goodman
Stock Analyst at Leerink Partners
(2.94)
# 1,642
Out of 4,761 analysts
97
Total ratings
56.41%
Success rate
28.15%
Average return
Main Sectors:
Stocks Rated by Marc Goodman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Maintains: Outperform | $110 → $150 | $137.75 | +8.89% | 7 | Feb 10, 2025 | |
| RLMD Relmada Therapeutics | Downgrades: Market Perform | $10 → $1 | $0.30 | +238.98% | 3 | Dec 4, 2024 | |
| BHVN Biohaven | Maintains: Outperform | $55 → $60 | $36.91 | +62.56% | 6 | Sep 23, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $32 | $23.49 | +36.23% | 1 | Apr 15, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: Market Perform | n/a | $3.30 | - | 4 | Mar 11, 2024 | |
| BLTE Belite Bio | Initiates: Outperform | $25 | $57.00 | -56.14% | 1 | Jul 26, 2023 | |
| DNLI Denali Therapeutics | Initiates: Outperform | $50 | $20.73 | +141.20% | 1 | Jan 30, 2023 | |
| EOLS Evolus | Maintains: Outperform | $18 → $20 | $13.99 | +42.96% | 3 | Jan 19, 2023 | |
| NBIX Neurocrine Biosciences | Maintains: Market Perform | $100 → $115 | $120.69 | -4.71% | 4 | Nov 2, 2022 | |
| BIIB Biogen | Maintains: Outperform | $270 → $310 | $140.64 | +120.42% | 11 | Oct 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $12 | $8.41 | +42.69% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $46 | $39.73 | +15.78% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $21 | $19.95 | +5.26% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $210 | $136.01 | +54.40% | 5 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $40 | $7.31 | +447.20% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.65 | +277.36% | 2 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $24 → $27 | $35.32 | -23.56% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $5.02 | +398.01% | 1 | Apr 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $70 | $128.60 | -45.57% | 3 | Apr 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $15 | $6.69 | +124.22% | 2 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $270 | $361.54 | -25.32% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $79 → $96 | $202.08 | -52.49% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $55.83 | - | 2 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $67 | $89.50 | -25.14% | 3 | Oct 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $98 | $25.34 | +286.74% | 7 | Oct 5, 2017 |
Axsome Therapeutics
Feb 10, 2025
Maintains: Outperform
Price Target: $110 → $150
Current: $137.75
Upside: +8.89%
Relmada Therapeutics
Dec 4, 2024
Downgrades: Market Perform
Price Target: $10 → $1
Current: $0.30
Upside: +238.98%
Biohaven
Sep 23, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $36.91
Upside: +62.56%
LENZ Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: $32
Current: $23.49
Upside: +36.23%
Amylyx Pharmaceuticals
Mar 11, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.30
Upside: -
Belite Bio
Jul 26, 2023
Initiates: Outperform
Price Target: $25
Current: $57.00
Upside: -56.14%
Denali Therapeutics
Jan 30, 2023
Initiates: Outperform
Price Target: $50
Current: $20.73
Upside: +141.20%
Evolus
Jan 19, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $13.99
Upside: +42.96%
Neurocrine Biosciences
Nov 2, 2022
Maintains: Market Perform
Price Target: $100 → $115
Current: $120.69
Upside: -4.71%
Biogen
Oct 26, 2022
Maintains: Outperform
Price Target: $270 → $310
Current: $140.64
Upside: +120.42%
Aug 11, 2022
Maintains: Outperform
Price Target: $6 → $12
Current: $8.41
Upside: +42.69%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $46
Current: $39.73
Upside: +15.78%
Aug 9, 2022
Maintains: Outperform
Price Target: $27 → $21
Current: $19.95
Upside: +5.26%
Aug 4, 2022
Maintains: Outperform
Price Target: $200 → $210
Current: $136.01
Upside: +54.40%
Jul 11, 2022
Maintains: Market Perform
Price Target: $50 → $40
Current: $7.31
Upside: +447.20%
Jul 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.65
Upside: +277.36%
Apr 28, 2022
Maintains: Market Perform
Price Target: $24 → $27
Current: $35.32
Upside: -23.56%
Apr 26, 2022
Initiates: Outperform
Price Target: $25
Current: $5.02
Upside: +398.01%
Apr 21, 2022
Maintains: Outperform
Price Target: $65 → $70
Current: $128.60
Upside: -45.57%
Dec 21, 2021
Maintains: Outperform
Price Target: $24 → $15
Current: $6.69
Upside: +124.22%
Mar 13, 2020
Maintains: Buy
Price Target: $300 → $270
Current: $361.54
Upside: -25.32%
Nov 19, 2019
Maintains: Buy
Price Target: $79 → $96
Current: $202.08
Upside: -52.49%
May 21, 2018
Downgrades: Neutral
Price Target: n/a
Current: $55.83
Upside: -
Oct 30, 2017
Maintains: Buy
Price Target: $72 → $67
Current: $89.50
Upside: -25.14%
Oct 5, 2017
Maintains: Buy
Price Target: $84 → $98
Current: $25.34
Upside: +286.74%